Base excision repair defects invoke hypersensitivity to PARP inhibition

Area of Science:

• Molecular Biology
• DNA Repair Mechanisms
• Cancer Therapeutics

Background:

• Poly (ADP-ribose) polymerase-1 (PARP-1) is crucial for recognizing and repairing DNA damage.
• PARP-1 activation involves PARylation, recruiting repair factors like XRCC1 and DNA polymerase β (pol β).
• PARP inhibitors (PARPi) block PARylation, stabilizing PARP-1 at damage sites and impeding repair.

Purpose of the Study:

• To investigate the impact of base excision repair (BER) deficiency on cellular sensitivity to PARP inhibitors (PARPi).
• To explore the therapeutic potential of targeting BER-deficient cells with PARPi.

Main Methods:

• Utilizing pol β(-/-) and Xrcc1(-/-) deficient cell lines to model BER deficiency.
• Assessing cellular hypersensitivity to PARP inhibitors, including 4-AN, olaparib, and veliparib.
• Evaluating the reversal of hypersensitivity upon reexpression of pol β or XRCC1.

Main Results:

• BER-deficient cells (pol β(-/-) and Xrcc1(-/-)) exhibited significant hypersensitivity to PARPi.
• Reintroducing pol β or XRCC1 reversed the hypersensitivity phenotype.
• BER deficiencies led to replication defects and double-strand DNA break (DSB)-induced apoptosis upon PARPi treatment.

Conclusions:

• Base excision repair (BER) deficiency confers heightened sensitivity to PARP inhibitors (PARPi).
• Targeting BER-deficient cancer cells with PARPi represents a promising therapeutic strategy.
• This finding opens new avenues for enhancing PARPi efficacy in cancer therapy.